diff --git a/domains/health/psilocybin-therapy-requires-psychological-support-as-embedded-protocol-component.md b/domains/health/psilocybin-therapy-requires-psychological-support-as-embedded-protocol-component.md index e4048f9f5..859377c01 100644 --- a/domains/health/psilocybin-therapy-requires-psychological-support-as-embedded-protocol-component.md +++ b/domains/health/psilocybin-therapy-requires-psychological-support-as-embedded-protocol-component.md @@ -11,9 +11,16 @@ sourced_from: health/2025-06-23-compass-pathways-comp005-psilocybin-phase3-trd.m scope: structural sourcer: Compass Pathways supports: ["behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"] -related: ["cognitive-behavioral-therapy-provides-durable-relapse-protection-through-skill-acquisition-unlike-pharmacological-interventions", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"] +related: ["cognitive-behavioral-therapy-provides-durable-relapse-protection-through-skill-acquisition-unlike-pharmacological-interventions", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "psilocybin-therapy-requires-psychological-support-as-embedded-protocol-component", "psychedelic-therapy-regulatory-success-requires-active-comparator-or-objective-endpoints-for-highly-psychoactive-compounds", "psilocybin-achieves-positive-phase3-trd-single-dose-26week-durability"] --- # Psilocybin therapy requires psychological support as an embedded clinical protocol component not an optional adjunct The COMP005 trial embedded psychological support as a mandatory protocol component across three phases: pre-session preparation, monitored dosing session (with trained facilitators present throughout the 6-8 hour experience), and post-session integration sessions. This design choice indicates that psilocybin therapy is not purely pharmacological but rather a hybrid intervention where the drug enables a psychological process that requires professional support to translate into clinical benefit. The trial's positive results cannot be attributed to the molecule alone but rather to the complete protocol package. This has significant implications for clinical implementation: psilocybin therapy will require specialized training infrastructure, dedicated session spaces, and multi-hour clinician time per patient—creating a fundamentally different delivery model than traditional psychiatric pharmacotherapy. The psychological support requirement also creates a natural quality control mechanism that may prevent the commoditization pathway seen with other psychiatric medications. This sits at the clinical/non-clinical interface: the pharmacological mechanism (5-HT2A agonism, neuroplasticity) is necessary but not sufficient; the psychological meaning-making process enabled by the drug state appears essential for durable benefit. The FDA approval pathway will need to specify not just the molecule but the complete therapeutic protocol, creating precedent for regulating hybrid pharmacological-psychological interventions. + + +## Extending Evidence + +**Source:** Sheri Eckert Foundation data via OPB 2025-07-03 + +The $670,000 philanthropic fund serving 100 people ($6,700/person) illustrates the cost structure of psilocybin therapy with proper support infrastructure. At market rates ($1,500-3,000/session plus facilitator training overhead), there is no viable path to population-scale access without insurance coverage. The economics require either massive subsidy or reimbursement infrastructure that does not currently exist. diff --git a/entities/health/oregon-sb-303.md b/entities/health/oregon-sb-303.md new file mode 100644 index 000000000..d36a2f284 --- /dev/null +++ b/entities/health/oregon-sb-303.md @@ -0,0 +1,28 @@ +--- +type: entity +entity_type: protocol +name: Oregon SB 303 +domain: health +passed: 2023 +status: active +tags: [psilocybin, Oregon, demographic-data, equity, policy] +--- + +# Oregon SB 303 + +## Overview +Oregon legislation (2023) requiring mandatory demographic data collection for psilocybin service clients under Measure 109, beginning January 2025. + +## Key Provisions +- Mandatory demographic data collection per administration session +- Quarterly aggregated reporting by Oregon Health Authority +- Voluntary income disclosure by clients +- Data collection began January 1, 2025 + +## Significance +SB 303 created the first systematic demographic tracking infrastructure for state-regulated psilocybin services, enabling empirical assessment of access equity. Q1 2025 data revealed significant income disparities in service utilization. + +## Timeline +- **2023** — SB 303 passed by Oregon legislature +- **2025-01-01** — Mandatory demographic data collection begins +- **2025-07-03** — Q1 2025 data released showing average client income of $153,000 \ No newline at end of file diff --git a/entities/health/sheri-eckert-foundation.md b/entities/health/sheri-eckert-foundation.md new file mode 100644 index 000000000..9dfedcef1 --- /dev/null +++ b/entities/health/sheri-eckert-foundation.md @@ -0,0 +1,26 @@ +--- +type: entity +entity_type: organization +name: Sheri Eckert Foundation +domain: health +founded: [Unknown] +status: active +website: [Not provided] +tags: [psilocybin, Oregon, access, equity, philanthropy] +--- + +# Sheri Eckert Foundation + +## Overview +Philanthropic organization providing subsidized access to psilocybin therapy services in Oregon under Measure 109. + +## Key Activities +- Raised $670,000+ to provide subsidized psilocybin therapy access +- Served 100+ people through subsidized services +- Maintains waitlists with hundreds of additional applicants + +## Significance +The Foundation's operations illustrate the scale mismatch between latent demand for psilocybin therapy among lower-income populations and available subsidized supply. At ~$6,700 per subsidized client, the philanthropic model cannot scale to population-level access. + +## Timeline +- **2025-07-03** — Reported having raised $670,000+ and served 100+ people, with hundreds more on waitlists for subsidized psilocybin services \ No newline at end of file diff --git a/inbox/queue/2025-07-03-opb-oregon-psilocybin-clients-wealthier-sb303-data.md b/inbox/archive/health/2025-07-03-opb-oregon-psilocybin-clients-wealthier-sb303-data.md similarity index 98% rename from inbox/queue/2025-07-03-opb-oregon-psilocybin-clients-wealthier-sb303-data.md rename to inbox/archive/health/2025-07-03-opb-oregon-psilocybin-clients-wealthier-sb303-data.md index 145930f1d..c839e01f3 100644 --- a/inbox/queue/2025-07-03-opb-oregon-psilocybin-clients-wealthier-sb303-data.md +++ b/inbox/archive/health/2025-07-03-opb-oregon-psilocybin-clients-wealthier-sb303-data.md @@ -7,10 +7,13 @@ date: 2025-07-03 domain: health secondary_domains: [] format: article -status: unprocessed +status: processed +processed_by: vida +processed_date: 2026-05-11 priority: high tags: [psilocybin, Oregon, equity, access, income-disparity, SB303, demographic-data, mental-health-supply-gap] intake_tier: research-task +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content